Cargando…
Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase
The mammalian target of rapamycin (mTOR) and phosphoinositide-3-kinase (PI3K) pathways are often aberrantly activated in acute myeloid leukemia (AML) and play critical roles in proliferation and survival of leukemia cells. We provide evidence that simultaneous targeting of mTOR complexes with the ca...
Autores principales: | Colamonici, Marco, Blyth, Gavin, Saleiro, Diana, Szilard, Amy, Bliss-Moreau, Meghan, Giles, Francis J., Altman, Jessica K., Beauchamp, Elspeth M., Platanias, Leonidas C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480735/ https://www.ncbi.nlm.nih.gov/pubmed/25823922 |
Ejemplares similares
-
Pharmacological mTOR targeting enhances the antineoplastic effects of selective PI3Kα inhibition in medulloblastoma
por: Eckerdt, Frank, et al.
Publicado: (2019) -
Targeting mTOR for the treatment of AML. New agents and new directions
por: Altman, Jessica K., et al.
Publicado: (2011) -
Inhibitory effects of Tomivosertib in acute myeloid leukemia
por: Suarez, Milagros, et al.
Publicado: (2021) -
Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias
por: Curi, Dany A., et al.
Publicado: (2015) -
ULK1 in type I interferon response
por: Saleiro, Diana, et al.
Publicado: (2015)